LI
AIMT

Leap Investments’s Aimmune Therapeutics AIMT Stock Holding History

Leap Investments’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$560K Buy
33,500
+20,100
+150% +$341K 0.37% 93
2020
Q1 		$193K Buy
+13,400
New +$343K 0.28% 159

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Leap Investments's AIMT Position: Q2 2020 in Review

Leap Investments increased its Aimmune Therapeutics (AIMT) stake by 150% in Q2 2020, buying an estimated $341K and bringing the position to 33,500 shares worth $560K. The position accounts for 0.37% of the portfolio, ranked #93.

Leap Investments first reported a position in AIMT in Q1 2020 and has held it in 2 quarters since. 165 funds tracked by Wall St. Rank hold AIMT as of Q2 2020.

  • Leap Investments held 33,500 shares of Aimmune Therapeutics worth $560K as of Q2 2020.
  • Leap Investments bought 20,100 Aimmune Therapeutics shares in Q2 2020, an estimated $341K.
  • Aimmune Therapeutics made up 0.37% of Leap Investments's portfolio in Q2 2020, its #93 holding.
  • Leap Investments first reported a position in Aimmune Therapeutics in Q1 2020 and has held it in 2 quarters since.
  • 165 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.